Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma DOI Creative Commons
Paramesh Karandikar, L. Suh, Jakob V. E. Gerstl

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 11

Published: Oct. 4, 2023

Oncolytic viral (OV) therapies are promising novel treatment modalities for cancers refractory to conventional treatment, such as glioblastoma, within the central nervous system (CNS). Although OVs have received regulatory approval use in CNS, efficacy is hampered by obstacles related delivery, under-/over-active immune responses, and "immune-cold" nature of most CNS malignancies. SUMO, Small Ubiquitin-like Modifier, a family proteins that serve high-level regulator large variety key physiologic processes including host response. The SUMO pathway has also been implicated pathogenesis both wild-type viruses As such, intersection OV biology with makes SUMOtherapeutics particularly interesting adjuvant enhancement alone concert other immunotherapeutic agents. Accordingly, authors herein provide: 1) an overview its role malignancies; 2) describe current state CNS-targeted OVs; 3) interplay between lifecycle

Language: Английский

Stimulator of interferon genes/Interferon regulatory factor 3 (STING-IRF3) and inflammasome-activation mediated pyroptosis biomarkers: a network of integrated pathways in diabetic nephropathy DOI
Omnia Safwat El‐Deeb, Yasser Mostafa Hafez, Amira Kamel Eltokhy

et al.

Journal of Diabetes & Metabolic Disorders, Journal Year: 2023, Volume and Issue: 22(2), P. 1471 - 1480

Published: Aug. 9, 2023

Language: Английский

Citations

4
Porcine deltacoronavirus nonstructural protein 2 inhibits type I and III IFN production by targeting STING for degradation DOI Creative Commons

Xiqian Liu,

Likai Ji, Yuqiang Cheng

et al.

Veterinary Research, Journal Year: 2024, Volume and Issue: 55(1)

Published: June 17, 2024

Abstract Porcine deltacoronavirus (PDCoV) is an enteropathogenic coronavirus that has been reported to use various strategies counter the host antiviral innate immune response. The cGAS-STING signalling pathway plays important role in immunity. However, it remains unclear whether PDCoV achieves evasion by regulating pathway. Here, we demonstrated nonstructural protein 2 (nsp2) encoded inhibits cGAS-STING-mediated type I and III interferon (IFN) responses via regulation of porcine STING (pSTING) stability. Mechanistically, ectopically expressed nsp2 was found interact with N-terminal region pSTING. Consequently, pSTING degraded through K48-linked ubiquitination proteasomal pathway, leading disruption signalling. Furthermore, K150 K236 were identified as crucial residues for nsp2-mediated degradation. In summary, our findings provide a basis elucidating mechanism will contribute development targets anti-coronavirus drugs.

Language: Английский

Citations

1
RNF39 facilitates antiviral immune responses by promoting K63-linked ubiquitination of STING DOI Creative Commons
Wenwen Wang, Qi Li, Mutian Jia

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 142, P. 113091 - 113091

Published: Sept. 9, 2024

Language: Английский

Citations

1
Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy DOI Creative Commons
Yurui Zhang, Yudi Wang,

Peizheng Mu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 11, 2024

Adaptive anti-tumor immunity is currently dependent on the natural immune system of body. The emergence tumor immunotherapy has improved prognosis and prolonged survival cycle patients. Current mainstream immunotherapies, including checkpoint blockade, chimeric antigen receptor T-cell immunotherapy, monoclonal antibody therapy, are linked to immunity. cGAS-STING pathway an important signaling that plays role in fighting against invasion foreign pathogens maintaining homeostasis organism. Increasing evidence suggests a key immunity, combination STING-related agonists can significantly enhance efficacy reduce immunotherapeutic resistance. However, double-edged sword, its activation immunosuppression. Immunosuppressive cells, M2 macrophages, MDSC, regulatory T microenvironment play crucial escape, thereby affecting effect. bi-directionally regulate this group immunosuppressive targeting affect function providing new ideas for immunotherapy. In study, we summarize immunological elaborate escape mediated by microenvironment. Finally, approaches related explore ways improve them, guidelines further clinical services.

Language: Английский

Citations

1
Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma DOI Creative Commons
Paramesh Karandikar, L. Suh, Jakob V. E. Gerstl

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 11

Published: Oct. 4, 2023

Oncolytic viral (OV) therapies are promising novel treatment modalities for cancers refractory to conventional treatment, such as glioblastoma, within the central nervous system (CNS). Although OVs have received regulatory approval use in CNS, efficacy is hampered by obstacles related delivery, under-/over-active immune responses, and "immune-cold" nature of most CNS malignancies. SUMO, Small Ubiquitin-like Modifier, a family proteins that serve high-level regulator large variety key physiologic processes including host response. The SUMO pathway has also been implicated pathogenesis both wild-type viruses As such, intersection OV biology with makes SUMOtherapeutics particularly interesting adjuvant enhancement alone concert other immunotherapeutic agents. Accordingly, authors herein provide: 1) an overview its role malignancies; 2) describe current state CNS-targeted OVs; 3) interplay between lifecycle

Language: Английский

Citations

2